Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Dongdong Xia
mRECIST Response Combined With Sorafenib-Related Adverse Events Is Superior to Either Criterion Alone in Predicting Survival in HCC Patients Treated With TACE Plus Sorafenib
International Journal of Cancer
Cancer Research
Oncology
Related publications
Changing TACTICS in Intermediate HCC: TACE Plus Sorafenib
Gut
Gastroenterology
Letter: Are Sorafenib-Related Adverse Events Associated With Prolonged Survival? Authors' Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial
Journal of Hepatology
Hepatology
Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
Gastroenterology Research
Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
Journal of Hepatocellular Carcinoma
Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC?
Hepatology
Medicine
Hepatology
Multimodality 3D Tumor Segmentation in HCC Patients Treated With TACE
Journal of Vascular and Interventional Radiology
Nuclear Medicine
Radiology
Cardiology
Cardiovascular Medicine
Imaging
Medicine
Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib
Clinical Genitourinary Cancer
Oncology
Urology
The Efficacy of TACE Combined Sorafenib in Advanced Stages Hepatocellullar Carcinoma
BMC Cancer
Cancer Research
Oncology
Genetics
